Industrial Biotechnology Innovation Centre (IBioIC), the specialist body set up to stimulate growth in the Industrial Biotechnology (IB) sector, is strengthening its team with the creation of three new roles.

The appointments expand the expertise of the IBioIC team as they support the sector in the delivery of the National Plan for Industrial Biotechnology, which aims to grow the IB sector to £900 million in turnover and have over 200 companies operating in IB by 2025.

Caroline Kewney and Russell Clarke both join as Senior Business Engagement Managers and will support the wider development of IB networks through industry and academia partnerships, supporting businesses scale-up, assisting companies to build collaborations, and helping them to access funding opportunities.

Caroline brings over 25 years’ experience in the health biotechnology sector, with experience in viral and microbiological biosafety, process validation and GMP biomanufacturing of biopharmaceuticals. She has held operational and commercial roles with BioReliance, BioOutsource and SGS in Scotland as well as a period of relocation to set up a facility in the US with Q-One Biotech. Her strategic role in supporting clients from small biotech to large pharma on their drug development journey to bring novel products to market has involved working with a range of clients and regulatory bodies globally across European, Asian and US markets.

Russell joins IBioIC from CalaChem Ltd where he spent the past eight years working across supply chains, operations and commercial teams.  Over the course of his 27 years in industry, Russell has gained a wealth of commercial experience through roles with Fine Organics, Dow Chemical and Thomas Swan, where he headed up the Contract Manufacturing Business Unit as Commercial Director.

The third appointment in the trio sees Debbie McCreath take up the role of Public Affairs Manager.  Debbie joins from the Food and Drink Federation and will lead on IBioIC’s stakeholder engagement activities, working across skills, education and policy areas.

Commenting on the new roles, Mark Bustard, CEO of IBioIC said: “I am delighted that Russell, Caroline and Debbie have joined our team at IBioIC. This new trio of appointments will strengthen IBioIC’s industrial links during the current period of economic uncertainty caused by COVID-19, and steer the industrial biotechnology community closer towards delivering the ambitious targets set out in the National Plan for Industrial Biotechnology.”

Since inception in 2014, IBioIC has overseen the doubling of industrial biotech in Scotland to over £350m and supports over 130 companies, over 50 research projects and 18 Scottish universities and research institutes.